Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity.

Endocrinol Diabetes Metab · 2022 · PMC9659655 · PMID 36239048

Europe PMC DOI

hedged sentences

0.0510

closest p · 1.0× alpha

0.0920

boldest claim

The sentences

very close to statistical significancep = .051so close (0.05 < p ≤ 0.1)

LS mean difference between treatment groups was 183.25 (95% CI: −1.17, 367.67) pmol/m 2 /mmol/L, which was very close to statistical significance ( p = .051, Figure 5B , Table 2 ).

also in 143 other papers

did not reach statistical significancep = .092so close (0.05 < p ≤ 0.1)

The decrease in pre‐dose FPG did not reach statistical significance ( p = .092, Table 2 ). 3.4 Insulin secretion in response to glucose To elucidate the mechanisms by which imeglimin exerted positive effects on glycaemic control, we calculated multiple parameters to assess its action on insulin secretion and β‐cell function.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.